Abstract：
OBJECTIVE: Colistin sulphate for injection (CSI) became clinically available in China in July 2019. To date, there is no published data regarding its usage in children. Our research group has been following data on the efficacy and safety of CSI in Chinese paediatric patients with carbapenem-resistant organism infections. The purpose of this short communication is to provide a brief overview of the findings to date.
METHODS: We reviewed the electronic medical records of paediatric patients (aged 9-17 y) who were administered CSI during their hospital stay at Tongji Hospital in Wuhan, China, between June 2021 and November 2023. Drug efficacy was evaluated based on clinical and microbiological outcomes, while drug safety was assessed using surveillance markers that reflect adverse reactions.
RESULTS: A total of 20 patients met the inclusion criteria. The predominant pathogens were Klebsiella pneumoniae (8 strains), followed by Acinetobacter baumannii (5 strains) and Pseudomonas aeruginosa (2 strains). The clinical response rate of CSI was 85%, with a bacterial clearance rate of 79%. None of the patients experienced colistin-related nephrotoxicity or neurotoxicity during the treatment.
CONCLUSIONS: In this real-world setting, CSI demonstrated a high level of clinical response and was well tolerated for the treatment of carbapenem-resistant organism infections in Chinese children.
METHODS: We reviewed the electronic medical records of paediatric patients (aged 9-17 y) who were administered CSI during their hospital stay at Tongji Hospital in Wuhan, China, between June 2021 and November 2023. Drug efficacy was evaluated based on clinical and microbiological outcomes, while drug safety was assessed using surveillance markers that reflect adverse reactions.
RESULTS: A total of 20 patients met the inclusion criteria. The predominant pathogens were Klebsiella pneumoniae (8 strains), followed by Acinetobacter baumannii (5 strains) and Pseudomonas aeruginosa (2 strains). The clinical response rate of CSI was 85%, with a bacterial clearance rate of 79%. None of the patients experienced colistin-related nephrotoxicity or neurotoxicity during the treatment.
CONCLUSIONS: In this real-world setting, CSI demonstrated a high level of clinical response and was well tolerated for the treatment of carbapenem-resistant organism infections in Chinese children.
摘要：
目的：注射用硫酸粘菌素（CSI）于2019年7月在中国临床上市。迄今为止,没有关于其在儿童中使用的公开数据。我们的研究小组一直在关注CSI在碳青霉烯类耐药菌（CRO）感染中国儿科患者中的疗效和安全性数据。本简短通讯的目的是简要概述迄今为止的调查结果。
方法：我们回顾了在武汉同济医院住院期间接受CSI的儿科患者（9-17岁）的电子病历，中国,2021年6月至2023年11月。根据临床和微生物学结果评估药物疗效，而使用反映不良反应的监测标志物评估药物安全性.
结果：共有20例患者符合纳入标准。主要病原菌为肺炎克雷伯菌(8株),其次是鲍曼不动杆菌(5株)和铜绿假单胞菌(2株)。CSI的临床应答率为85%,细菌清除率为79%。在治疗期间，没有患者出现粘菌素相关的肾毒性或神经毒性。
结论：在现实世界中，CSI表现出高水平的临床反应，并且对中国儿童CRO感染的治疗具有良好的耐受性。
方法：我们回顾了在武汉同济医院住院期间接受CSI的儿科患者（9-17岁）的电子病历，中国,2021年6月至2023年11月。根据临床和微生物学结果评估药物疗效，而使用反映不良反应的监测标志物评估药物安全性.
结果：共有20例患者符合纳入标准。主要病原菌为肺炎克雷伯菌(8株),其次是鲍曼不动杆菌(5株)和铜绿假单胞菌(2株)。CSI的临床应答率为85%,细菌清除率为79%。在治疗期间，没有患者出现粘菌素相关的肾毒性或神经毒性。
结论：在现实世界中，CSI表现出高水平的临床反应，并且对中国儿童CRO感染的治疗具有良好的耐受性。
